Completed
Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects
NCT00651105
- Conditions
- Diabetes Mellitus, Endocrine System Diseases, Glucose Metabolism Disorders, +5 more
- Locations
-
- Novartis Investigator Site Bad Lauterberg im Harz, Germany
- Novartis Investigator Site Berlin, Germany